FindTrial
Sign In

CC-486 (5-azacitidine)

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Adult T-cell Leukemia/LymphomaCutaneous T-Cell LymphomaEnteropathy-Associated T-Cell LymphomaExtranodal NK-/T-cell Lymphoma, Nasal TypeHepatosplenic T-cell LymphomaMature T-cell MalignanciesMonomorphic Epiteliotrophic Intestinal T-cell LymphomaPeripheral T-Cell Lymphoma

Phase 1

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
CompletedNCT04447027
National Cancer Institute (NCI)Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma +1
Start: 2020-12-17End: 2025-12-17Updated: 2026-01-30
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
WithdrawnNCT04639843
National Cancer Institute (NCI)Adult T-cell Leukemia/Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type +2
Start: 2022-11-03End: 2022-11-03Updated: 2022-11-04

Related Papers

Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
Blood2024-11-052 citations
Abstract PO-007: A phase 1 study of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
Blood Cancer Discovery2024-06-19